Showing 81 - 100 results of 215,380 for search '(( 1 1 decrease ) OR ( 5 ((((non decrease) OR (point decrease))) OR (a decrease)) ))', query time: 1.95s Refine Results
  1. 81
  2. 82
  3. 83
  4. 84

    Inclusion of SRRM4-regulated exons is decreased in tumors and cancer cell lines. by Sarah A. Head (6066398)

    Published 2021
    “…(B) SRRM4 target exons with respect to their average PSI in normal tissues. Red points are exons with PSI decreasing by at least 5% in at least 1 tumor type. …”
  5. 85
  6. 86
  7. 87
  8. 88

    Mice carrying 100P mutations show layer-specific decreases in proportions of PV+ cells. by Malgorzata Borkowska (3166719)

    Published 2016
    “…<p>(<b>A-D</b>) Decreases occurred in layer IV in fSSp, SSp, vAud and Vis, in layer V in SSp, vAud and Vis and in layer II/III in SSp. …”
  9. 89

    Dopaminergic Neurodegeneration in the Mouse Is Associated with Decrease of Viscoelasticity of Substantia Nigra Tissue by Elisabeth G. Hain (542261)

    Published 2016
    “…Therefore, MRE measurements of the SN, midbrain and hippocampus were performed in adult female mice before and at five time points after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin hydrochloride (MPTP) treatment specifically lesioning dopaminergic neurons in the SN. …”
  10. 90

    Targeting <i>A20</i> decreases glioma stem cell survival. by Anita B. Hjelmeland (104655)

    Published 2010
    “…<p>(A) Annexin V staining demonstrates increased apoptosis with <i>A20</i> targeting in glioma stem cells isolated from a D317 glioma xenograft or a T3359 patient specimen passaged short term in immunocompromised mice. …”
  11. 91
  12. 92

    Transforming growth factor (TGF)-β1 induced a robust decrease in S-phase in non-cancer cell strains by Kimberly A Brown (26546)

    Published 2011
    “…Representative histograms are presented illustrating cells that had a robust decrease in S-phase (NMuMG), modest decrease in S-phase (EpH4), and no decrease in S-phase (MDA-MB-436) as a result of TGF-βtreatment. …”
  13. 93
  14. 94
  15. 95
  16. 96
  17. 97
  18. 98
  19. 99
  20. 100

    Example of K<sup>trans</sup> decrease during therapy. by Jean-Philip Daniel Weber (12213395)

    Published 2022
    “…<p>NSCLC of the left upper lobe showing a clear decrease of K<sup>trans</sup> from baseline (left) to first follow-up after 1 week of checkpoint inhibition by Erlotinib and Bevacizumab.…”